{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:29:39Z","timestamp":1760236179484,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The aim of our study will be to evaluate the effect of combining pelvic floor muscle training (PFMT) with the urgency-suppression technique and silodosin in comparison with silodosin alone in men with Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB) after 12 weeks of treatment. The primary outcome will be a change in the number of voidings and intensity of urgencies over 24 h using a micturition diary, and the secondary outcomes will be a change in lower urinary tract symptoms, a change in incontinence quality of life, a change in patients\u2019 global impression of improvement, and a lower incidence of adverse events. A randomized intervention parallel multicenter study will be conducted in collaboration with 45 urological clinics at the national level. Patients will be assigned at a 1:1 ratio to the experimental and control groups using simple randomization according to odd and even patient sequence numbers in each ambulatory clinic. The experimental group will receive oral silodosin at a daily dose of 8 mg once daily and pelvic floor muscle training (PFMT) 5 times a week for 20\u201330 min a day, for 12 weeks. The control group will receive oral treatment with silodosin at a daily dose of 8 mg once daily for 12 weeks. The study protocol presents the starting points and design of a randomized, interventional, parallel, multicenter study looking at the effect of a combination of silodosin and PFMT versus silodosin treatment in men with BPH and OAB.<\/jats:p>","DOI":"10.3390\/ijerph182111426","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T22:21:34Z","timestamp":1635805294000},"page":"11426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)"],"prefix":"10.3390","volume":"18","author":[{"given":"Magdalena","family":"Hagovska","sequence":"first","affiliation":[{"name":"Department of Physiatry, Balneology, and Medical Rehabilitation, Faculty of Medicine, PJ Safarik University, 040 01 Kosice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-6359","authenticated-orcid":false,"given":"Jan","family":"Svihra","sequence":"additional","affiliation":[{"name":"Department of Urology, Jessenius Faculty of Medicine, Martin, Comenius University, 814 99 Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int. Urogynecol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_3","unstructured":"Chapple, C., and Abrams, P. (2013). Male Lower Urinary Tract Symptom (LUTS), Societe Internationale d\u2019Urologie (SIU)."},{"key":"ref_4","unstructured":"Gravas, S., Cornu, J.N., Gacci, M., Gratzke, C., Herrmann, T.R.W., Mamoulakis, C., Rieken, M., Speakman, M.J., and Tikkinen, K.A.O. (2021, October 07). European Association of Urology EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), Incl. Benign Prostatic Obstruction (BPO). Available online: https:\/\/uroweb.org\/guideline\/treatment-of-non-neurogenic-male-luts\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","article-title":"Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men","volume":"98","author":"Kawabe","year":"2006","journal-title":"BJU Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","article-title":"Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies","volume":"181","author":"Marks","year":"2009","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","article-title":"Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers","volume":"56","author":"Chapple","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Silva, V., Grande, A.J., and Peccin, M.S. (2019). Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD012044.pub2"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","article-title":"Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction:a prospective, randomized, controlled study","volume":"169","author":"Athanasopoulos","year":"2003","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/nau.23935","article-title":"Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies","volume":"38","author":"Matsukawa","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/nau.23107","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction","volume":"36","author":"Bo","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2490-12-26","article-title":"Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder","volume":"12","author":"Notte","year":"2012","journal-title":"BMC Urol."},{"key":"ref_14","unstructured":"Cockett, A.T.K., Aso, Y., Chatelain, C., Denis, L., Griffiths, K., Khoury, S., and Murphy, G. (1991, January 26\u201327). Recommendations of the International Concensus Committee Concerning Prostate Symptom Score (I-PSS) and quality of life assesment. Proceedings of the International Consultation on BPH. International Scientific Committee, Paris, France."},{"key":"ref_15","unstructured":"Cockett, A.T.K., Khoury, S., Aso, Y., Chatelain, C., Denis, L., Griffiths, K., and Murphy, G. (1993, January 27\u201330). Recommendations of the International Consensus Committee. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, France."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s11136-004-0706-1","article-title":"The responsiveness of the Overactive Bladder Questionnaire (OAB-q)","volume":"14","author":"Coyne","year":"2005","journal-title":"Qual. Life Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual. Life Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.juro.2007.03.133","article-title":"Validation of the overactive bladder symptom score","volume":"178","author":"Blaivas","year":"2007","journal-title":"J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","article-title":"Solifenacin in the treatment of urgency and other symptoms of overactive bladder: Results from a randomized, doubleblind, placebo-controlled, rising-dose trial","volume":"102","author":"Cardozo","year":"2008","journal-title":"BJU Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0022-5347(09)61944-3","article-title":"Retrograde ejaculation induced by silodosin is the result of relaxation of smooth musculature in the male uro-genital tracts and is associated with greater urodynamic and symptomatic improvements in men LUTS secondary to BPH","volume":"181","author":"Roehrborn","year":"2009","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00192-014-2417-7","article-title":"Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder","volume":"25","author":"Cardozo","year":"2014","journal-title":"Int. Urogynecol. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1067\/mob.2003.379","article-title":"Validation of two global impression questionnaires for incontinence","volume":"189","author":"Yalcin","year":"2003","journal-title":"Am. J. Obstet. Gynecol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/21\/11426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:23Z","timestamp":1760167403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/21\/11426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":22,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijerph182111426"],"URL":"https:\/\/doi.org\/10.3390\/ijerph182111426","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2021,10,30]]}}}